Sichuan Dowell Science and Technology Inc. (300535.SZ)
CNY 14.37
(0.07%)
CNY 14.37
(0.07%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 59.77 Million | 45.81 Million | 53.58 Million | -27.34 Million | 30.98 Million | -776.83 Thousand |
| Net Income | 3.55 Million | -17.2 Million | 65.68 Million | 55.43 Million | 39.29 Million | 41.23 Million |
| Depreciation & Amortization | 42.09 Million | 35.36 Million | 34.68 Million | 34.75 Million | 24.95 Million | 17.72 Million |
| Deferred income taxes | 1.13 Million | 2.57 Million | 126.39 Thousand | -563.19 Thousand | -2.75 Million | 52.51 Thousand |
| Stock-based compensation | - | 1.73 Million | 4.51 Million | 7.67 Million | 10.86 Million | 13.37 Million |
| Change in working capital | -42.99 Million | 3.29 Million | -63 Million | -132.28 Million | -38.82 Million | -58.43 Million |
| Other non-cash items | 12.49 Million | 24.35 Million | 16.22 Million | 14.74 Million | 5.56 Million | -1.3 Million |
| Investing Cash Flow | -96.47 Million | -124.9 Million | -154.62 Million | 6.79 Million | -53.87 Million | -49.94 Million |
| Investments in PPE | -98.25 Million | -59.75 Million | -107.31 Million | -27.62 Million | -57.09 Million | -74.97 Million |
| Acquisitions | 177.92 Thousand | 29.8 Thousand | 941.02 Thousand | 87.44 Thousand | 57.13 Million | 75.07 Million |
| Investment purchases | -10.8 Million | -62.7 Million | -48.25 Million | -80.9 Million | -288.2 Million | -592.73 Million |
| Sales/Maturities of investments | - | 122.82 Thousand | -941.02 Thousand | 112.4 Million | 291.36 Million | 617.64 Million |
| Other Investing Activities | 12.4 Million | -2.59 Million | 941.02 Thousand | 2.82 Million | -57.09 Million | -74.97 Million |
| Financing Cash Flow | 44.64 Million | 94.27 Million | 86.81 Million | 47.5 Million | 18.1 Million | -11.71 Million |
| Debt repayment | -50 Million | -140 Million | -92 Million | -10 Million | - | - |
| Dividends payments | -8.44 Million | -10.45 Million | -9.38 Million | -8.29 Million | -10.46 Million | -11.4 Million |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | 3.08 Million | 250.59 Million | 191.63 Million | 66.75 Million | 28.56 Million | -312.19 Thousand |
| Accounts receivables | -72.57 Million | 42.62 Million | -26.74 Million | -104.03 Million | -37.79 Million | -29.46 Million |
| Accounts payables | 28.8 Million | -50.1 Million | 31.13 Million | 29.21 Million | 22.13 Million | -15.48 Million |
| Inventory | -365.13 Thousand | 8.19 Million | -67.52 Million | -56.9 Million | -20.41 Million | -13.53 Million |
| Other working capital | 338.19 Thousand | 2.57 Million | 126.39 Thousand | -563.19 Thousand | -2.75 Million | -44.89 Million |
| Cash at beginning of period | 59.65 Million | 43.71 Million | 58.75 Million | 33.77 Million | 38.4 Million | 100.62 Million |
| Cash at end of period | 68.65 Million | 59.65 Million | 43.71 Million | 58.75 Million | 33.77 Million | 38.4 Million |
| Capital Expenditure | -98.25 Million | -59.75 Million | -107.31 Million | -27.62 Million | -57.09 Million | -74.97 Million |
| Effect of forex changes on cash | 1.05 Million | 748.84 Thousand | -818.78 Thousand | -1.97 Million | 155.59 Thousand | 231.68 Thousand |
| Net cash flow / Change in cash | 8.99 Million | 15.93 Million | -15.03 Million | 24.97 Million | -4.62 Million | -62.21 Million |
| Free Cash Flow | -38.48 Million | -13.94 Million | -53.72 Million | -54.97 Million | -26.1 Million | -75.74 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -813.80 | 22.22 Million | 7.95 Million | 3.55 Million | -5.02 Million | 18.59 Million |
| Depreciation & Amortization | - | 9.55 Million | 9.55 Million | 42.09 Million | 42.09 Million | -16.31 Million |
| Deferred income taxes | - | - | - | 1.13 Million | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | -50.41 Million | - | -42.99 Million | -72.6 Million | 3.76 Million |
| Other non-cash items | 31.04 Million | 323.7 Thousand | -29.77 Million | 12.49 Million | 58.45 Million | 13.7 Million |
| Investing Cash Flow | -27.91 Million | -23.99 Million | -33.61 Million | -96.47 Million | -8.52 Million | -17.05 Million |
| Investments in PPE | -27.81 Million | -24 Million | -33.38 Million | -98.25 Million | -24.23 Million | -16.79 Million |
| Acquisitions | 5524.23 | 312.46 Thousand | 66.69 Thousand | 177.92 Thousand | 15.00 | 36.37 Thousand |
| Investment purchases | -100 Thousand | -300 Thousand | -300 Thousand | -10.8 Million | 3.3 Million | -300 Thousand |
| Sales/Maturities of investments | - | - | - | - | - | -36.37 Thousand |
| Other Investing Activities | 5524.23 | 12.46 Thousand | -233.3 Thousand | 12.4 Million | 15.7 Million | 36.37 Thousand |
| Financing Cash Flow | 4.54 Million | 7.33 Million | 57.56 Million | 44.64 Million | 13.17 Million | 8.39 Million |
| Debt repayment | -4.7 Million | -10 Million | -60 Million | -50 Million | -15.55 Million | -30 Million |
| Dividends payments | -10.16 Million | -2.66 Million | -2.43 Million | -8.44 Million | -2.37 Million | -2.16 Million |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | 10 Million | -2.66 Million | -2.43 Million | 3.08 Million | 15.55 Million | 40.56 Million |
| Accounts receivables | - | -26.28 Million | - | -72.57 Million | -72.57 Million | 11.44 Million |
| Accounts payables | - | - | - | 28.8 Million | - | - |
| Inventory | - | -24.53 Million | - | -365.13 Thousand | -365.13 Thousand | -3.75 Million |
| Other working capital | - | 410.49 Thousand | - | 338.19 Thousand | 338.19 Thousand | -3.92 Million |
| Cash at beginning of period | 68.12 Million | 71.25 Million | 68.66 Million | 59.65 Million | 41.16 Million | 28.08 Million |
| Cash at end of period | 76.49 Million | 68.12 Million | 71.26 Million | 68.65 Million | 68.65 Million | 41.16 Million |
| Capital Expenditure | -27.81 Million | -24 Million | -33.38 Million | -98.25 Million | -24.23 Million | -16.79 Million |
| Effect of forex changes on cash | 685.93 Thousand | 535.14 Thousand | 475.68 Thousand | 1.05 Million | 15.91 Million | -14.01 Million |
| Net cash flow / Change in cash | 8.36 Million | -3.12 Million | 2.6 Million | 8.99 Million | 27.48 Million | 13.08 Million |
| Free Cash Flow | 3.22 Million | -11 Million | -55.2 Million | -38.48 Million | -1.3 Million | 2.95 Million |
300891
2360
000927
LIPPISYS
FBDS
024890